Hagop Kantarjian: Impact of MRD clearance kinetics in patients with AML undergoing intensive chemotherapy
Hagop Kantarjian, Professor and Chair of the Department of Leukemia at The University of Texas MD Anderson Cancer Center, posted on X about recent paper by Wei-Ying Jen et al., titled “Impact of measurable residual disease clearance kinetics in patients with AML undergoing intensive chemotherapy” published on Blood Advances.
Authors: Wei-Ying Jen, Koji Sasaki, Farhad Ravandi, Tapan M. Kadia, Sa A. Wang, Wei Wang, Sanam Loghavi, Naval G. Daver, Courtney D. DiNardo, Ghayas C. Issa, Hussein A. Abbas, Cedric Nasnas, Alex Bataller, Samuel Urrutia, Omer S. Karrar, Sherry Pierce, Hagop M. Kantarjian, Nicholas J. Short
“Early attainment of undetectable MRD by MFC is independently associated with improved RFS in newly diagnosed AML. Intermediate risk pts who attain undetectable MRD should still undergo consolidative allo-SCT.”
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023